| PE | Sector PE | P/B | Div. Yield | ROE |
|---|---|---|---|---|
| 41.82 | 28.92 | 2.85 | -- | 6.8% |
Vilin Bio Med received an order from the Hyderabad bench of the National Company Law Tribunal allowing the first-stage application for its proposed merger with Chemgenix Laboratories. The tribunal dispensed with Chemgenix's shareholder meeting and ordered meetings of its creditors and Vilin Bio Med's public shareholders and creditors for 15 October 2026 in Hyderabad. Under the proposed scheme, Vilin Bio Med would issue one ₹10 share for each of Chemgenix's 96.9 lakh shares, while shares held by Vilin Bio Med in Chemgenix would be cancelled. Chemgenix was described as a developer and manufacturer of oncology APIs and specialty chemicals, while Vilin Bio Med makes oral liquids, dry syrups, tablets, capsules and nutritional supplements. Vilin Bio Med's FY23 annual record showed paid-up capital of ₹9.95 crore and profit of ₹1.25 crore, with no revenue figure disclosed.
Powered by Tijori
Vilin Bio Med received an order from the Hyderabad bench of the National Company Law Tribunal allowing the first-stage application for its proposed merger with Chemgenix Laboratories. The tribunal dispensed with Chemgenix's shareholder meeting and ordered meetings of its creditors and Vilin Bio Med's public shareholders and creditors for 15 October 2026 in Hyderabad. Under the proposed scheme, Vilin Bio Med would issue one ₹10 share for each of Chemgenix's 96.9 lakh shares, while shares held by Vilin Bio Med in Chemgenix would be cancelled. Chemgenix was described as a developer and manufacturer of oncology APIs and specialty chemicals, while Vilin Bio Med makes oral liquids, dry syrups, tablets, capsules and nutritional supplements. Vilin Bio Med's FY23 annual record showed paid-up capital of ₹9.95 crore and profit of ₹1.25 crore, with no revenue figure disclosed.
Powered by Tijori
July 14 (Reuters) - Vilin Bio Med Ltd VILI.NS:
VILIN BIO MED - TO INCORPORATE VILO SPECIALITY PHARMA AND AXIA PHARMA AS WHOLLY OWNED SUBSIDIARIES
Source text: ID:nNSEbjwMSc
Further company coverage: VILI.NS
July 14 (Reuters) - Vilin Bio Med Ltd VILI.NS:
VILIN BIO MED - TO INCORPORATE VILO SPECIALITY PHARMA AND AXIA PHARMA AS WHOLLY OWNED SUBSIDIARIES
Source text: ID:nNSEbjwMSc
Further company coverage: VILI.NS
Jan 10 (Reuters) - Vilin Bio Med Ltd VILI.NS:
VILIN BIO MED LTD - CHILAM SRIKANTH RESIGNS AS CFO
Source text: ID:nNSEb3Hr2b
Further company coverage: VILI.NS
Jan 10 (Reuters) - Vilin Bio Med Ltd VILI.NS:
VILIN BIO MED LTD - CHILAM SRIKANTH RESIGNS AS CFO
Source text: ID:nNSEb3Hr2b
Further company coverage: VILI.NS
Oct 3 (Reuters) - Vilin Bio Med Ltd VILI.NS:
VISWA PRASAD SADHANALA RESIGNS AS MANAGING DIRECTOR
NAMES YADAMAKANTI MADHU SUDHAN REDDY AS MANAGING DIRECTOR
Source text for Eikon: ID:nNSE6PLm1
Further company coverage: VILI.NS
Oct 3 (Reuters) - Vilin Bio Med Ltd VILI.NS:
VISWA PRASAD SADHANALA RESIGNS AS MANAGING DIRECTOR
NAMES YADAMAKANTI MADHU SUDHAN REDDY AS MANAGING DIRECTOR
Source text for Eikon: ID:nNSE6PLm1
Further company coverage: VILI.NS
Oct 23 (Reuters) - Vilin Bio Med Ltd VILI.NS:
INTIMATION REGARDING TEMPORARY SUSPENSION OF OPERATION AT THE MANUFACTURING OF UNIT
OPERATIONS AT MANUFRCTURING UNIT SITUATED AT UNIT IN UTTARAKHAND HAVE BEEN TEMPORARILY SUSPENDED
SUSPENSION PER DIRECTION OF THE INSPECTOR OF DRUGS, HARIDWAR, FDA, AND FOR CARRYING OUT MAINTENANCE ACTIVITIES
Source text for Eikon: ID:nNSE8SlTj7
Further company coverage: VILI.NS
Oct 23 (Reuters) - Vilin Bio Med Ltd VILI.NS:
INTIMATION REGARDING TEMPORARY SUSPENSION OF OPERATION AT THE MANUFACTURING OF UNIT
OPERATIONS AT MANUFRCTURING UNIT SITUATED AT UNIT IN UTTARAKHAND HAVE BEEN TEMPORARILY SUSPENDED
SUSPENSION PER DIRECTION OF THE INSPECTOR OF DRUGS, HARIDWAR, FDA, AND FOR CARRYING OUT MAINTENANCE ACTIVITIES
Source text for Eikon: ID:nNSE8SlTj7
Further company coverage: VILI.NS
| Mar 26(Cr.) | YoY Change | QoQ Change | |
|---|---|---|---|
| Sales | 32.60 | -- | -- |
| Operating Profit | 2.86 | -- | -- |
| Net profit | 1.78 | -- | -- |
| Type | Jun 26 | Sep 26 | YoY Change | QoQ Change |
|---|---|---|---|---|
| Promoter | 56.65% | 56.65% | -7.24% | -- |
| Pledge | -- | -- | -- | -- |
| FII | -- | 0.13% | 0.13% | 0.13% |
| DII | -- | -- | -- | -- |
| Retail < 2L | 24.43% | 24.99% | -1.52% | 0.56% |
| Others | 18.92% | 18.23% | -- | -0.69% |
| No. of Shareholders | 382 | 384 | -19.33% | 0.52% |
| Name | M.CAP (Cr.) | PE | ROCE (%) | D/E |
|---|---|---|---|---|
| VILINBIO | 81.00 | 41.82 | 10.21 | 0.01 |
| SAMRATPH | 80.00 | -- | -2.95 | 0.16 |
| VINRKLB | 81.00 | -- | 41.27 | -0.74 |
| VINEETLAB | 73.00 | 20.90 | 10.73 | 0.99 |